-
-
-
-
-
-
-
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
-
-
-
-
-
-
-
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance
-
-
-
-
-
-
-
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
-
-
-
-
-
-
-
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
-
-
-
-
-
-
-
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
-
-
-
-
-
-
-
Ligand Pharma (LGND) Acquires Royalty on Sanofi’s (SNY) TZIELD for $20 Million
-
-
-
-
-
-
-
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
-
1,158,060 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

